Alexander Olawaiye, MD, on The ROSELLA Trial in Platinum-Resistant Ovarian Cancer

Posted: Friday, June 13, 2025

Alexander Olawaiye, MD, of the University of Pittsburgh School of Medicine and Magee-Women’s Hospital, reviews data from the phase III ROSELLA trial, which looked at the selective glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. 

---